英語 での Adverse events の使用例とその 日本語 への翻訳
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
-
Programming
Results for cardiovascular events and short-term serious adverse events were also uncertain.
心血管イベントと短期の重篤な有害事象の結果も不確かでした。Adverse events were not reported in a manner suitable for analysis, and rates of depression remission and quality of life were not reported.
Adverse events were consistent with those previously reported for Avastin, and no new Avastin safety signals were observed in the study.
有害事象は以前にAvastinで報告されたものと一致し、新たな安全性シグナルは観察されませんでした。Both severe and non-severe adverse events were reported, but the true nature and extent of harm was difficult to asses.
重度および非重度の有害事象の両者が報告されていたが、有害性の真の性質や程度の評価は困難であった。Dialysis providers also should be aware of their responsibility to report clusters of infections or other adverse events to the appropriate local or state public health authority.
また、透析施設は感染症や他の有害事象の発生を適切な地域または州の公衆衛生局に報告しなければならない。The overall incidence of adverse events was low and did not differ between the two groups.
有害な事象の発生率は低く、両グループに差はありませんでした。The total incidence of adverse events and of serious adverse effects were similar in all the treatment groups.
全有害事象および重篤な有害事象の発生は，全群で同程度であった。Adverse events were reported by 83% of patients during the zonisamide treatment period and by 74% during the placebo period.
有害事象はゾニサミド治療期間中で患者の83％、プラセボ期間中では74％の報告があった。There were no statistically significant differences in immune-related adverse events between elderly and younger patients(P=0.535).
毒性については、高齢患者と若年患者との間の免疫関連有害事象に統計的有意差は認められなかった（P＝0.535）。Secondary end points included death, serious adverse events, hip-related complications, health-related quality of life, function, and overall health end points.
副次エンドポイントは、死亡、重篤有害事象、股関節関連の合併症、健康関連QOL、機能、全体的な健康エンドポイントなどだった。Nausea and vomiting are the most commonly reported adverse events and Roche denies any dangerous side effects of its drug.
嘔気と嘔吐が最もよく報告される有害事象であり、ロシュ社は危険な副作用に関しては完全に否定している。Further study in a larger group of patients is required to determine the success rate, durability, and longer-term adverse events with this treatment.”.
この治療の成功率、永続性び長期における有害事象を調査するためには、より大きな患者群での研究が必要です」。There is also insufficient evidence to determine the difference in withdrawals due to adverse events between patients treated with garlic or placebo.
ニンニク投与群とプラセボ投与群で有害事象による試験中止の差を判断するエビデンスも不十分である。The incidence of on-treatment serious adverse events(SAEs) were 23.2% on FF/VI 100/25mcg and 22.2% on placebo.
治療期間中の重篤な有害事象の発現率は、FF/VI100/25mcg群23.2%、プラセボ群22.2%でした。Discontinuation due to treatment- related adverse events was less frequent with Opdivo(5%) than docetaxel(15%).
薬剤関連有害事象による中止も、オプジーボ（5%）の方がドセタキセル（15%）よりも低い結果となりました。The proportion of people who experienced adverse events increased to 23.6 percent at 3 years and 35.7 percent at 5 years.
有害事象を経験した人々の割合は、3年間で23.6％、5年間で35.7％に増加しました。No clinically significant differences in adverse events were observed between the two groups, and there was no evidence of benefit after discontinuation of nicotinamide.
群間に有害事象について臨床的に有意な差は認められず、ニコチンアミド中止後の有益性の証拠は認められなかった。In addition, there were no clinically relevant gender-based differences in adverse events.
加えて、有害事象に関して、臨床的に性別に関連した相違は認められなかった。Adverse events were not well reported, no information is available on mortality, morbidity and costs.
有害事象については適切に報告されておらず、死亡率、罹病率および費用に関する情報は入手できなかった。Of the individuals reporting such adverse events, five were discontinued from the study of their own accord or by the doctor's order.
このような有害事象を報告した被験者のうち、5例は自分の意思又は医師の命令によって試験を中止した。
